These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22732666)

  • 1. In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant.
    Rizzi A; Campi B; Camarda V; Molinari S; Cantoreggi S; Regoli D; Pietra C; Calo' G
    Peptides; 2012 Sep; 37(1):86-97. PubMed ID: 22732666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant.
    Ruzza C; Rizzi A; Malfacini D; Molinari S; Giuliano C; Lovati E; Pietra C; Calo' G
    Peptides; 2015 Jul; 69():26-32. PubMed ID: 25843024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
    Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects.
    Stathis M; Pietra C; Rojas C; Slusher BS
    Eur J Pharmacol; 2012 Aug; 689(1-3):25-30. PubMed ID: 22683863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LY303870, a centrally active neurokinin-1 antagonist with a long duration of action.
    Iyengar S; Hipskind PA; Gehlert DR; Schober D; Lobb KL; Nixon JA; Helton DR; Kallman MJ; Boucher S; Couture R; Li DL; Simmons RM
    J Pharmacol Exp Ther; 1997 Feb; 280(2):774-85. PubMed ID: 9023291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents.
    Brocco M; Dekeyne A; Mannoury la Cour C; Touzard M; Girardon S; Veiga S; de Nanteuil G; deJong TR; Olivier B; Millan MJ
    Eur Neuropsychopharmacol; 2008 Oct; 18(10):729-50. PubMed ID: 18657401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
    Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
    Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
    Nordquist RE; Durkin S; Jacquet A; Spooren W
    Eur J Pharmacol; 2008 Dec; 600(1-3):87-92. PubMed ID: 18930726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
    Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
    Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological properties of FK886, a new, centrally active neurokinin-1 receptor antagonist.
    Yoshino-Furukawa T; Maeda Y; Kikuchi A; Sakuma H; Imazumi K; Yamakuni H; Sogabe H; Matsuo M; Manda T; Uchida W
    Biol Pharm Bull; 2013; 36(1):76-81. PubMed ID: 23302639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role for NK(1) and NK(2) receptors in the motor activity in mouse colon.
    Mulè F; Amato A; Serio R
    Eur J Pharmacol; 2007 Sep; 570(1-3):196-202. PubMed ID: 17597603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
    Malherbe P; Knoflach F; Hernandez MC; Hoffmann T; Schnider P; Porter RH; Wettstein JG; Ballard TM; Spooren W; Steward L
    Br J Pharmacol; 2011 Feb; 162(4):929-46. PubMed ID: 21039418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
    Kudlacz EM; Shatzer SA; Knippenberg RW; Logan DE; Poirot M; van Giersbergen PL; Burkholder TP
    J Pharmacol Exp Ther; 1996 May; 277(2):840-51. PubMed ID: 8627566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism by imidazoline-type drugs of muscarinic and other receptors in the guinea-pig ileum.
    Salazar-Bookaman MM; Miller DD; Patil PN
    Auton Autacoid Pharmacol; 2006 Jul; 26(3):267-73. PubMed ID: 16879492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
    Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
    J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors.
    Engberg S; Ahlstedt I; Leffler A; Lindström E; Kristensson E; Svensson A; Påhlman I; Johansson A; Drmota T; von Mentzer B
    Biochem Pharmacol; 2007 Jan; 73(2):259-69. PubMed ID: 17097619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
    Hale JJ; Mills SG; MacCoss M; Finke PE; Cascieri MA; Sadowski S; Ber E; Chicchi GG; Kurtz M; Metzger J; Eiermann G; Tsou NN; Tattersall FD; Rupniak NM; Williams AR; Rycroft W; Hargreaves R; MacIntyre DE
    J Med Chem; 1998 Nov; 41(23):4607-14. PubMed ID: 9804700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of selective antagonists for further characterization of tachykinin NK-2, NK-1 and possible "septide-selective" receptors in guinea pig bronchus.
    Zeng XP; Burcher E
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1295-300. PubMed ID: 7523658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.